News & Updates
Showing Dermatology articles
Showing
Show Multimedia Only

TIL therapy still effective in advanced melanoma despite prior anti-PD-(L)1 treatment
21 Oct 2024
byStephen Padilla
The clinical response or survival benefit derived by patients with advanced cutaneous melanoma from adoptive cell therapy with tumor-infiltrating lymphocytes (TIL-ACT) does not wane even with prior antiprogrammed cell death protein 1/programmed death-ligand 1 (anti-PD-[L]1) treatment, according to a study. TIL therapy also provides benefits in the second-line setting after anti-PD-(L)1 treatment.
21 Oct 2024







